1. Introduction
The rapid evolution of diagnostic technologies reflects a growing need for tools that are not only accurate and sensitive but also accessible and adaptable across diverse clinical environments. Over the past two decades, biosensors have emerged as one of the most promising platforms for improving diagnostic workflows, enabling earlier detection of disease, reducing turnaround time, and supporting decentralized testing models. Traditional laboratory-based methods—such as ELISA, culture techniques, PCR amplification, and chromatography—remain effective but often require skilled personnel, lengthy processing times, and sophisticated instrumentation (Li & Liu, 2017). As disease burdens increase globally and health systems face pressure to adopt faster, low-cost solutions, biosensors offer an attractive alternative grounded in biochemical specificity and engineering precision (Wang, 2016).
This introduction provides a comprehensive overview of biosensor technologies from the perspective of a systematic review and meta-analysis. Through an evidence-based approach, it synthesizes trends, evaluates diagnostic performance, and contextualizes the strengths and limitations of biosensors used in modern clinical settings. Systematic reviews draw together diverse findings to build cohesive insight, while meta-analyses mathematically integrate data to quantify overall diagnostic performance. Together, they form a robust foundation for assessing the effectiveness of biosensor platforms across biomedical applications.
Biosensors broadly function by converting a biological interaction—typically between a target analyte and a recognition element—into a measurable signal. Early biosensor development centered on enzyme-based glucose sensors, but technological advancements have since expanded the field to include antibodies, nucleic acids, aptamers, microbes, and nanomaterials as recognition elements (Turner, 2013). Concurrent improvements in electrochemical transduction, fluorescence detection, plasmonics, and piezoelectric signal processing have driven increased sensitivity and decreased limits of detection. Systematic evidence shows that modern biosensors can detect biomarkers at concentrations far lower than conventional assays, often within minutes and using micro-scale sample volumes (Pundir & Chawla, 2018).
The methodology of a systematic review requires rigorous database searches, transparent inclusion criteria, and structured data extraction. Following PRISMA guidelines enables researchers to identify trends and isolate methodological variables that influence biosensor performance. Many included studies compare biosensor results directly with established clinical gold standards, enabling quantification of diagnostic sensitivity, specificity, and accuracy. The application of meta-analysis strengthens these comparisons by producing pooled performance measures through random-effects modeling, accounting for heterogeneity between studies with different fabrication techniques, analyte types, and study populations (Higgins & Green, 2011).
Across the reviewed literature, one of the strongest emerging trends is the incorporation of nanomaterials—such as gold nanoparticles, graphene, carbon nanotubes, and metal–organic frameworks—into biosensor designs. Nanomaterials increase surface area, enhance electron transfer, and improve signal amplification, resulting in lower detection limits and heightened response stability (Zhang et al., 2015). Studies consistently show that nanostructured electrodes outperform unmodified ones, particularly in electrochemical biosensing applications where electron transfer kinetics are crucial. The review also highlights increasing interest in microfluidics-integrated biosensors, which facilitate automated sample handling, rapid reaction kinetics, and device miniaturization suitable for point-of-care testing.
Despite their advantages, biosensors face challenges that contribute to variability in diagnostic outcomes. Many studies included in the review reported issues with signal drift, environmental sensitivity, irreversible biofouling, and lot-to-lot inconsistencies in sensor fabrication (Singh & Mishra, 2017). Calibration remains a significant limitation, as biosensor responses can differ when transitioning from controlled lab conditions to real biological samples, especially in complex matrices such as blood, plasma, or wastewater. These challenges were reflected in the between-study heterogeneity identified in meta-analytic modeling. While pooled diagnostic performance remained high overall, variation in reproducibility and long-term stability indicated the need for standardized fabrication protocols and unified analytical validation procedures.
Clinical applicability is another central theme in the systematic evidence. Biosensors have been widely evaluated for infectious diseases, metabolic disorders, cancer biomarkers, cardiovascular diseases, and environmental contaminants. Electrochemical biosensors, in particular, have shown high promise for cardiac biomarkers such as troponin, C-reactive protein, and myoglobin, offering portable alternatives to large immunoassay analyzers (Hernandez et al., 2016). Optical biosensors have demonstrated exceptional sensitivity for nucleic acids and protein markers relevant to cancers and viral infections (Qavi & Bailey, 2010). Consistent with the findings of this review, biosensors generally exhibit strong correlation with laboratory benchmarks while providing faster results, enabling both emergency assessments and remote testing scenarios.
The broader implications of integrating biosensor technologies into healthcare systems are significant. As low-cost, high-sensitivity platforms, biosensors have the potential to reduce diagnostic inequities in low-resource settings, enhance disease surveillance, and improve personalized treatment strategies. Their compatibility with smartphones, wearable devices, and wireless monitoring systems positions them as central to the future of telemedicine and digital health. Systematic evidence suggests that ongoing technological innovation—involving AI-driven data interpretation, nanomaterial engineering, and portable microfluidics—will continue to expand diagnostic capabilities and overcome current biosensor limitations.
In summary, the systematic review and meta-analysis approach provides strong support for the continued development and clinical integration of biosensor technologies. While challenges remain, especially related to reproducibility and performance standardization, the evidence clearly demonstrates the transformative potential of biosensors to enhance diagnostic accuracy, accelerate clinical decision-making, and support global health needs. Continued research, regulatory collaboration, and technological refinement will be essential to fully realize these benefits.